Physician profile
Howard Soh
NPI 1053767475
$3,300.06
in general payments reported to CMS, 2019-2025
23 companies · $2,047 in 2025
The $2,047 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $104 · 2024: $1,149 · 2025: $2,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.71 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $793.38 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $483.43 | 2023-2025 | Airsupra, Tezspire, Breztri |
| Amgen INC. | $271.98 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $255.06 | 2024-2025 | Dupixent |
| Genzyme Corporation | $254.35 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $162.92 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $160.03 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.65 | 2024-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Philips North America LLC | $149.17 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Insmed, INC. | $100.70 | 2024-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $75.49 | 2025 | |
| Genentech USA, INC. | $72.08 | 2024-2025 | Xolair |
| Jazz Pharmaceuticals INC. | $69.15 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.61 | 2024-2025 | Aralast |
| Bayer Healthcare Pharmaceuticals INC. | $52.50 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $42.66 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $30.71 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $27.69 | 2025 | |
| Lilly USA, LLC | $18.37 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $18.11 | 2024 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $17.75 | 2025 | Lumryz |
| Paratek Pharmaceuticals, INC. | $15.73 | 2024 | Nuzyra |
| Mylan Specialty L.P. | $15.54 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Soh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.